Welcome to our dedicated page for Elicio Therapeutics news (Ticker: ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.
Elicio Therapeutics reports developments as a clinical-stage biotechnology company developing cancer immunotherapies. Company news centers on its proprietary Amphiphile, or AMP, technology, the ELI-002 program, and immunotherapy work for mKRAS-positive cancers including pancreatic ductal adenocarcinoma, colorectal cancer, lung cancer, and other KRAS-driven tumors.
Recurring updates also include clinical and regulatory disclosures, operating and financial results, healthcare-conference presentations, shareholder voting and governance matters, capital-structure actions, and Nasdaq inducement stock option grants under the company’s 2024 Inducement Incentive Award Plan.
Elicio Therapeutics (Nasdaq: ELTX) closed a previously announced registered direct offering of 4,380,313 common shares, raising approximately $15 million in gross proceeds before fees.
The company plans to use funds to support Phase 1 development of ELI-002 7P in metastatic PDAC, advance its pipeline and platform, and for working capital and general corporate purposes.
Elicio Therapeutics (Nasdaq: ELTX) priced a registered direct offering of 4,380,313 common shares, led by two new institutional investors and a large existing shareholder. The deal is expected to raise about $15 million in gross proceeds, closing around July 6, 2026, subject to customary conditions.
According to Elicio, net proceeds plus existing cash will primarily fund planned Phase 1 development of ELI-002 7P in metastatic PDAC, its broader pipeline and platform, and general corporate purposes.
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech developing immunotherapies for KRAS-driven cancers, has been added to the Russell 2000 and Russell 3000 indexes, effective after the U.S. market close on June 26, 2026, following the 2026 Russell reconstitution.
The company views this as a milestone that broadens visibility with institutional investors as it advances its ELI-002 7P program.
Elicio Therapeutics (Nasdaq: ELTX) reported three metastatic mKRAS pancreatic cancer patients who progressed on ELI-002 7P in Phase 2 AMPLIFY-7P and later achieved 100% confirmed complete radiographic and metabolic responses after nivolumab-based therapy, with CA19-9 normalization and persistent mKRAS-specific T cells.
According to Elicio, these preliminary observations support evaluating ELI-002 7P with checkpoint inhibition. Subject to funding, the company plans a Phase 1 first-line metastatic PDAC study using gemcitabine/nab-paclitaxel plus anti–PD-1, designed for rapid clinical activity assessment.
Elicio Therapeutics (Nasdaq: ELTX) reported Phase 2 AMPLIFY-7P results in adjuvant mKRAS-driven pancreatic cancer. The study did not meet its primary DFS endpoint in the intent-to-treat population. Post-hoc analyses showed improved DFS in R0 resected patients (HR 0.65, p=0.048) and strong mKRAS-specific T cell correlations (HR 0.22, p<0.0001). ELI-002 7P showed a favorable safety profile with no treatment-related discontinuations or deaths. Guided by these data, Elicio plans a Phase 3 trial focused on R0 patients with extended dosing, subject to financing. The company expects existing cash to fund operations into Q4 2026.
Elicio Therapeutics (Nasdaq: ELTX) reported preclinical data in Science Advances on its lymph node-targeted AMP-DNA adjuvant platform. Studies in mice and non-human primates showed robust, polyfunctional CD8+ and CD4+ T cell responses, durable immune memory for at least nine months, and high neutralizing antibody titers.
AMP-DNA outperformed clinical and commercial benchmark adjuvants, enabled precise lymph node delivery, and drove immune activation through TBK1/IFN-I signaling, expanding Elicio’s AMP immunomodulator portfolio alongside AMP-CpG (ELI-004) for potential next-generation oncology and infectious disease immunotherapies.
Elicio Therapeutics (Nasdaq: ELTX) reported Q1 2026 results and clinical updates. The Phase 2 AMPLIFY-7P primary disease-free survival analysis of ELI-002 7P in post-resection mKRAS PDAC is expected mid-2026, with fewer progressions and deaths than projected.
Q1 R&D was $6.8M, G&A $3.8M, net loss $11.8M ($0.65/share). Cash was $14.9M on March 31, plus $13.0M raised via ATM, supporting operations into Q4 2026.
Elicio Therapeutics (Nasdaq: ELTX) will present at the Bank of America Healthcare Conference in Las Vegas on May 14, 2026 at 12:20 PM ET.
Presenters include CEO Robert Connelly, CMO Christopher Haqq, CSO Pete DeMuth, and CSFO Preetam Shah. A live webcast and 90-day replay are available via the company’s Events page. 1×1 meetings are arranged through Bank of America representatives.
Elicio Therapeutics (Nasdaq: ELTX) announced on April 16, 2026 that it granted 21,210 inducement stock options to a new employee, approved by the Compensation Committee under the 2024 Inducement Incentive Award Plan.
The options have a $11.78 per-share exercise price (Nasdaq closing price on April 15, 2026) and vest over four years: 25% on the first anniversary of employment, then monthly thereafter, subject to continued service and Nasdaq Listing Rule 5635(c)(4).
Elicio Therapeutics (Nasdaq: ELTX) granted an aggregate of 1,600 inducement stock options on March 16, 2026, to a newly hired employee under the 2024 Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have a strike price of $12.16 (Nasdaq closing price on March 16, 2026) and vest over four years with 25% vesting after one year and monthly ratable vesting thereafter, subject to continued service.